Complement activation cascade triggered by PEG-PL engineered nanomedicines and carbon nanotubes: The challenges ahead

Publication: Research - peer-reviewJournal article – Annual report year: 2010

  • Author: Moghimi, S.M.

    University of Copenhagen, Department of Pharmaceutics and Analytical Chemistry

  • Author: Andersen, A.J.

    University of Copenhagen, Department of Pharmaceutics and Analytical Chemistry

  • Author: Hashemi, S.H.

    University of Copenhagen, Department of Pharmaceutics and Analytical Chemistry

  • Author: Lettiero, B.

    University of Copenhagen, Department of Pharmaceutics and Analytical Chemistry

  • Author: Ahmadvand, D.

    University of Copenhagen, Department of Pharmaceutics and Analytical Chemistry

  • Author: Hunter, A.C.

    University of Brighton, School of Pharmacy

  • Author: Andresen, Thomas Lars

    Colloids and Biological Interfaces Group, Self-organizing materials for nanotechnology Section, Department of Micro- and Nanotechnology, Technical University of Denmark, Produktionstorvet, 2800, Kgs. Lyngby, Denmark

  • Author: Hamad, I.

    Applied Sciences University, Faculty of Pharmacy

  • Author: Szebeni, J.

    Semmelweis Medical University and Seroscience Kft, Bay Zoltán Foundation for Applied Research

View graph of relations

Since their introduction, poly(ethylene glycol)-phospholipid (PEG-PL) conjugates have found many applications in design and engineering of nanosized delivery systems for controlled delivery of pharmaceuticals especially to non-macrophage targets. However, there are reports of idiosyncratic reactions to certain PEG-PL engineered nanomedicines in both experimental animals and man. These reactions are classified as pseudoallergy and may be associated with cardiopulmonary disturbance and other related symptoms of anaphylaxis. Recent studies suggest that complement activation may be a contributing, but not a rate limiting factor, in eliciting hypersensitivity reactions to such nanomedicines in sensitive individuals. This is rather surprising since PEGylated structures are generally assumed to suppress protein adsorption and blood opsonization events including complement. Here, we examine the molecular basis of complement activation by PEG-PL engineered nanomedicines and carbon nanotubes and discuss the challenges ahead.
Original languageEnglish
JournalJournal of Controlled Release
Publication date2010
Volume146
Journal number2
Pages175-181
ISSN0168-3659
DOIs
StatePublished

Conference

ConferenceNanomedicine and Drug Delivery
CountryUnited States
CityIndianapolis
Period05/10/0906/10/09
CitationsWeb of Science® Times Cited: 51

Keywords

  • Micelle, Pseudoallergy, Poly(ethylene glycol), Complement activation, Liposome, Carbon nanotube
Download as:
Download as PDF
Select render style:
APAAuthorCBEHarvardMLAStandardVancouverShortLong
PDF
Download as HTML
Select render style:
APAAuthorCBEHarvardMLAStandardVancouverShortLong
HTML
Download as Word
Select render style:
APAAuthorCBEHarvardMLAStandardVancouverShortLong
Word

ID: 5133920